Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FLT3 mutation + NPM1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	ixazomib Resistant: D – Preclinical ixazomib Resistant : D	ixazomib Resistant: D – Preclinical ixazomib Resistant : D